Vivus Inc (VVUS):企業の財務・戦略的SWOT分析

◆英語タイトル:Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15902
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,625見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,875見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Vivus Inc (VVUS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet medical needs for the treatment of obesity, sleep apnea, diabetes, and sexual health. The company’s marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.

Vivus Inc Key Recent Developments

Feb 26,2019 VIVUS announces fourth quarter 2018 financial results
Jan 14,2019 Data Supporting the Cardiovascular Safety of VIVUS Qsymia Published in The Journal of Clinical Endocrinology & Metabolism
Nov 01,2018 VIVUS reports third quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Vivus Inc – Key Facts
Vivus Inc – Key Employees
Vivus Inc – Key Employee Biographies
Vivus Inc – Major Products and Services
Vivus Inc – History
Vivus Inc – Company Statement
Vivus Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Vivus Inc – Business Description
Product Category: License and Milestone Revenue
Performance
Product Category: Pancreaze – Royalty Revenue
Performance
Product Category: Pancreaze Net Product Revenue
Performance
Product Category: Qsymia
Performance
Product Category: Stendra/Spedra Royalty Revenue
Performance
Product Category: Supply Revenue
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Vivus Inc – SWOT Analysis
SWOT Analysis – Overview
Vivus Inc – Strengths
Vivus Inc – Weaknesses
Vivus Inc – Opportunities
Vivus Inc – Threats
Vivus Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Vivus Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 26, 2019: VIVUS announces fourth quarter 2018 financial results
Jan 14, 2019: Data Supporting the Cardiovascular Safety of VIVUS Qsymia Published in The Journal of Clinical Endocrinology & Metabolism
Nov 01, 2018: VIVUS reports third quarter 2018 financial results
Oct 29, 2018: VIVUS adds two new members to the Board of Directors
Oct 10, 2018: VIVUS to Present at the BIO Investor Forum on October 17, 2018
Sep 21, 2018: VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb
Aug 07, 2018: VIVUS reports second quarter 2018 financial results
Aug 06, 2018: VIVUS names Kenneth Suh as president
May 08, 2018: VIVUS Reports First Quarter 2018 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Vivus Inc, Key Facts
Vivus Inc, Key Employees
Vivus Inc, Key Employee Biographies
Vivus Inc, Major Products and Services
Vivus Inc, History
Vivus Inc, Subsidiaries
Vivus Inc, Key Competitors
Vivus Inc, Ratios based on current share price
Vivus Inc, Annual Ratios
Vivus Inc, Annual Ratios (Cont...1)
Vivus Inc, Annual Ratios (Cont...2)
Vivus Inc, Interim Ratios
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Vivus Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Vivus Inc, Performance Chart (2014 - 2018)
Vivus Inc, Ratio Charts
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Vivus Inc (VVUS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • William Hill PLC:企業の戦略・SWOT・財務分析
    William Hill PLC - Strategy, SWOT and Corporate Finance Report Summary William Hill PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Synexus Limited(製薬・医療分野):企業M&A動向
    Summary Synexus Limited (Synexus) is a pharmaceutical service provider. It recruits large volumes of patients to conduct clinical trials at the research centers on behalf of pharmaceutical and biotechnology companies and and contract research organizations. The service offerings of the company inclu …
  • Nutra Pharma Corp (NPHC):製薬・医療:M&Aディール及び事業提携情報
    Summary Nutra Pharma Corp (Nutra Pharma) acquires, licenses and commercializes pharmaceutical products, technologies, homeopathic drugs and ethical drugs for managing cancer, neurological disorders, autoimmune and infectious diseases, including human Immunodeficiency virus (HIV), multiple sclerosis …
  • Europaeische Reiseversicherung AG:企業の戦略・SWOT・財務情報
    Europaeische Reiseversicherung AG - Strategy, SWOT and Corporate Finance Report Summary Europaeische Reiseversicherung AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Alliqua BioMedical Inc (ALQA)-製薬・医療分野:企業M&A・提携分析
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s product categories include ultrasound healing therapy, human biologics, antimicrobial …
  • Hogan Lovells International LLP:企業の戦略的SWOT分析
    Hogan Lovells International LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Universe Bidco Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Universe Bidco Limited Mergers …
  • Merrex Gold, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Merrex Gold, Inc. Mergers and A …
  • Tiziana Life Sciences Plc (TILS):企業のM&A・提携動向(医療機器分野)
    Summary Tiziana Life Sciences Plc (Tiziana) formerly Alexander David Investments is a clinical stage biotechnology company that discovers and develops innovative drugs for the treatment of various types of cancer with particular focus on late stage metastases. Tiziana’ discovery of the Bcl-3 gene pl …
  • The Kansai Electric Power Company Inc:発電所・企業SWOT分析
    The Kansai Electric Power Company Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaEssentia Corp (PharmaEssentia) is a developer of therapeutic products for the treatment of human diseases. The company’s pipeline product includes P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. Its pegylation technology platform …
  • MicroJet Technology Co., Ltd. (8197):企業財務及び戦略的SWOT分析
    Summary MicroJet Technology Co., Ltd. (MicroJet) is a chemical company that offers printing products manufacturing services. The company designs and manufactures inkjet printheads, inkjet printers and piezo-electric devices. It offers inkjet printing products including inkjet print heads, inkjet pri …
  • Just Energy Group Inc. (JE):企業のM&A・提携動向(エネルギー分野)
    Summary Just Energy Group Inc. (Just Energy) is a provider of energy management solutions. The company offers natural gas, electricity, solar energy, green energy and energy efficiency tools and products to customers. The company business operations include the sale of natural gas and electricity to …
  • DandM Holdings, Inc. (doing business as The D+M Group):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' DandM Holdings, Inc. (doing bus …
  • Infinia Corporation, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Infinia Corporation, Inc. Merge …
  • Revance Therapeutics, Inc.:(医療機器分野)企業M&A及び提携動向
    Summary Revance Therapeutics, Inc. (Revance) is a bio-pharmaceutical company. The company develops, manufactures and commercializes novel botulinum toxin products for multiple aesthetic and therapeutic applications. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT …
  • Rolta India Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Rolta India Limited Mergers and …
  • Chubu Electric Power Co Inc (9502)-石油・ガス分野:企業M&A・提携分析
    Summary Chubu Electric Power Co Inc (Chubu) is an energy utility. It generates and procures electricity; and offers electric network related services. The company produces electricity from nuclear, hydro, solar, biomass, wind, coal, fuel oil, and natural gas sources. Chubu has interests in upstream …
  • Gordon Food Service Inc:企業の戦略的SWOT分析
    Gordon Food Service Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • GE Water & Process Technologies:企業概要及び戦略的SWOT分析
    GE Water & Process Technologies - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆